# Phathom Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Phathom Pharmaceuticals, Inc.). ## Overview Phathom Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing vonoprazan-based therapies for acid-related gastrointestinal diseases. Its commercial products include VOQUEZNA tablets, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK, which are marketed in the United States for conditions such as GERD and H. pylori infection. ## Products & services • VOQUEZNA tablets for acid-related GI disease • VOQUEZNA DUAL PAK for H. pylori treatment • VOQUEZNA TRIPLE PAK for H. pylori treatment • Vonoprazan development and regulatory programs • U.S. commercialization, access, and patient support - **Commercial prescription products** (85%) — Approved VOQUEZNA-branded therapies sold in the U.S. for GERD and H. pylori-related indications. - **Patient access and support services** (5%) — Third-party pharmacy support and access programs that help patients obtain and stay on therapy. - **Clinical development** (10%) — Research, clinical, and regulatory work to expand vonoprazan into additional indications and formulations. - VOQUEZNA tablets for acid-related GI disease - VOQUEZNA DUAL PAK for H. pylori treatment - VOQUEZNA TRIPLE PAK for H. pylori treatment - Vonoprazan development and regulatory programs - U.S. commercialization, access, and patient support ## Customers Phathom sells primarily into the U.S. prescription drug channel, with product flowing through wholesale distributors and select pharmacies before reaching patients, clinics, and institutions. Its commercial focus is on gastroenterologists, other high-prescribing healthcare providers, and select primary care physicians who treat GERD and H. pylori infection. Payer coverage and pharmacy access programs are important because they influence whether patients can start and continue therapy. - **Wholesale distributors** (primary) — Buy finished product in the U.S. channel and distribute it to pharmacies and other outlets; they are the main revenue conduit. - **Select pharmacies** (primary) — Purchase VOQUEZNA products for dispensing to retail, institutional, clinic, and cash-pay patients. - **Gastroenterologists** (primary) — High-prescribing specialists targeted for VOQUEZNA adoption in GERD and H. pylori treatment. - **Primary care physicians** (secondary) — Selected PCPs who treat acid-related disorders and can expand prescribing beyond specialists. - **Payers and pharmacy benefit managers** (primary) — Influence formulary placement, prior authorization, and patient out-of-pocket cost exposure. - Wholesale distributors that buy product for downstream pharmacy supply - Select pharmacies that dispense VOQUEZNA to patients and clinics - Gastroenterologists who prescribe for GERD and H. pylori infection - Primary care physicians who treat common acid-related GI disease - Payers and pharmacy benefit managers that determine access and coverage ## Geography Phathom is centered in the United States, where it commercializes VOQUEZNA and conducts most of its operating activity. The company also has licensing economics tied to sales in the United States, Europe, and Canada through its Takeda agreement, but the disclosed commercial revenue base is U.S.-focused. Geography matters because access, reimbursement, and distribution are organized around the U.S. healthcare system. - **United States** (100%) — Commercial revenue disclosed in the reports is from U.S. product sales. - United States is the core commercial market for VOQUEZNA - U.S. sales run through national wholesale and pharmacy channels - Commercial coverage depends on U.S. payer and formulary access - Takeda milestones/royalties reference U.S., Europe, and Canada - Headquarters are in Florham Park, New Jersey ## Strategy Phathom’s strategy is to expand adoption of VOQUEZNA by targeting high-prescribing gastroenterologists, selected primary care physicians, and patient access channels. It also seeks to broaden formulary coverage and support adherence through pharmacy services, while advancing vonoprazan into additional indications and formulations. The company’s commercial model depends on converting clinical awareness into repeat prescribing and maintaining access through payers and distributors. - **Increase U.S. prescription adoption** (short-term) — Revenue depends on converting specialist awareness into sustained VOQUEZNA prescribing. - **Improve payer access and formulary coverage** (short-term) — Coverage and prior authorization determine whether patients can start therapy and remain on treatment. - **Expand vonoprazan lifecycle opportunities** (medium-term) — Additional indications and formulations can extend the product franchise beyond the initial launch set. - Drive VOQUEZNA adoption among gastroenterologists and key prescribers - Expand payer coverage and formulary positioning to improve access - Use patient support programs to reduce friction and out-of-pocket cost - Leverage direct-to-consumer and digital education to build awareness - Advance vonoprazan development for additional indications/formulations ## Risks Phathom is highly dependent on the commercial success of a small number of VOQUEZNA products, so demand, payer access, and prescriber adoption are central risks. It also faces typical pharmaceutical risks around product liability, manufacturing and supply chain dependence, clinical development uncertainty, and reliance on third parties for distribution and patient access. Because the company is still building its commercial base, financing needs and execution risk remain important business constraints. - **Dependence on VOQUEZNA commercial success** [critical] — The company currently depends entirely on a small set of approved products, especially VOQUEZNA for GERD. - **Customer concentration** [high] — A small number of wholesale and retail customers account for a large share of product sales. - **Payer and reimbursement friction** [high] — Utilization management, step edits, and prior authorization can slow or block therapy initiation. - **Product liability claims** [high] — Pharmaceutical products can generate litigation tied to safety, labeling, or use in patients. - **Third-party supply and service dependence** [medium] — Manufacturing, distribution, and patient access rely on external vendors and support providers. - Heavy dependence on VOQUEZNA products and GERD demand - Payer coverage and prior authorization can limit patient access - Concentrated customer base increases channel and counterparty risk - Product liability exposure is inherent in marketed pharmaceuticals - Third-party manufacturing, CRO, and pharmacy support dependence ## Accounting The most important accounting judgments are revenue recognition for product sales, net of rebates, chargebacks, discounts, and other deductions, and the estimation of returns and payer-related adjustments. Cost of revenue also includes royalties to Takeda, shipping and handling, and inventory write-downs, so channel mix and launch timing can affect reported margins and period-to-period comparability. Clinical development costs, stock-based compensation, and milestone/royalty obligations also require judgment and can materially affect reported results. - **Revenue deductions and reserves** — Can materially change recognized revenue versus gross shipments - **Takeda royalties and milestones** — Affects cost of revenue and long-term cash obligations - **Inventory and excess/obsolete reserves** — Can increase cost of revenue and reduce reported gross margin - **Clinical development expense recognition** — Creates volatility tied to development activity - Net product revenue depends on rebate and chargeback estimates - Takeda royalties reduce gross margin and vary with U.S. sales - Inventory reserves can affect cost of revenue and launch economics - Clinical trial and CMC spending is expensed as incurred - Stock-based compensation and milestone obligations affect operating results --- *Last updated: 2026-04-29T04:48:34.977861+00:00*